Last reviewed · How we verify

NCT04096092: PLATO

Pharmacokinetics of Teicoplanin in Intensive Care and Haematology Patients

Completed Last updated 31 January 2023
What this trial tests

trial testing No intervention in Bacterial Infections in 30 participants. Completed in 1 December 2022.

Timeline
15 January 2020
Primary endpoint
19 October 2021
1 December 2022

Quick facts

Lead sponsorRadboud University Medical Center
StatusCompleted
Study typeOBSERVATIONAL
Enrollment30
Start date15 January 2020
Primary completion19 October 2021
Estimated completion1 December 2022
Sites1 location across Netherlands

Drugs / interventions tested

Conditions studied

Sponsor

Radboud University Medical Center

Who can join

18 and older, any sex, with Bacterial Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Characterize teicoplanin PK in critically ill patients with a specific focus on alterations of exposure due to variability in renal function. In a prospective, observational, open-label study the investigators aim to define PK of free drug concentrations of teicoplanine in ICU and heamatology patients and define a PK model for Bayesian dose individualization.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of No intervention

Trials testing the same drug.

Other recruiting trials for Bacterial Infections

Currently open trials in the same condition.

Other Radboud University Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04096092.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing